Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2023-A00350-45 | Registry Identifier | French Minister |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study of the microcirculation and glycocalyx could be an essential element in the monitoring of our patients undergoing major abdominal surgery. It would enable us to better target the objectives of anaesthesia and resuscitation, which until now have been based essentially on macro-circulatory parameters.
This monitoring is possible in real time and real conditions by micro-camera GlycoCheck™ (Microvascular Health Solutions Inc., Salt Lake City, Utah, USA), a non-invasive monitoring allowing the study of sublingual microcirculation and glycocalyx.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group HIPEC | Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) |
| |
| Group CDP | Cephalic DuodenoPancreatectomy (CDP) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy | Procedure | Cytoreduction surgery with Hyperthermic Intraperitoneal Chemotherapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Glycocalyx thickness | Perioperative variation in glycocalyx thickness (µm) | between the day before the operation (Day -1) and the post-operative period (Day 1) |
| Measure | Description | Time Frame |
|---|---|---|
| Glycocalyx thickness and a biological marker of tissue hypoperfusion | To assess, in each population ((HIPEC and CDC), the association between the thickness of the glycocalyx established by analysis of the sublingual microcirculation using GlycoCheck® and a biological marker of tissue hypoperfusion. | post-operative period (Day 1) |
Not provided
Inclusion Criteria:
For the HIPEC group :
For the CDP group :
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient undergoing major abdominal surgery by cytoreduction combined with an intraperitoneal chemotherapy bath (HIPEC) or cephalic duodeno-pancreatectomy (CDP) with epidural analgesia planned in accordance with the department's usual practice
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Zoé DEMAILLY, Dr | University Rouen Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rouen University Hospital | Rouen | 76000 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000084262 | Hyperthermic Intraperitoneal Chemotherapy |
| D003565 | Cytidine Diphosphate |
| ID | Term |
|---|---|
| D017024 | Chemotherapy, Adjuvant |
| D003131 | Combined Modality Therapy |
| D013812 | Therapeutics |
| D004358 | Drug Therapy |
Not provided
Not provided
Not provided
Not provided
Not provided
| Cephalic DuodenoPancreatectomy | Procedure | Cephalic DuodenoPancreatectomy |
|
|
| Glycocalyx thickness and a biological marker of tissue hypoxia |
Establish the link between glycocalyx thickness and a biological marker of tissue hypoxia. |
| post-operative period (Day 1) |
| Blood cell velocity and macrocirculatory function | Assess the association between velocity of the red blood cells (µm/s) and cardiac index obtained by Most-Care® monitoring on Day 1. | post-operative period (Day 1) |
| Perfused capillary density and macrocirculatory function | Assess the association between perfused capillary density (mm/mm2) and cardiac index obtained by Most-Care® monitoring on Day 1. | post-operative period (Day 1) |
| Variation of glycocalyx thickness and the daily entry-exit balance (BES) Day 1 | To assess the difference between water and fluid intake (perfusion, nutrition, drug dilution solution) and output (diuresis, digestive aspiration, diarrhoea) over 24 hours | between Day -1 and Day 1 |
| D006979 |
| Hyperthermia, Induced |
| D003597 | Cytosine Nucleotides |
| D011742 | Pyrimidine Nucleotides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D009711 | Nucleotides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D012265 | Ribonucleotides |